Last reviewed · How we verify
Insulin Detemir and RAI injection
Insulin Detemir and RAI injection is a Small molecule drug developed by Montefiore Medical Center. It is currently FDA-approved.
At a glance
| Generic name | Insulin Detemir and RAI injection |
|---|---|
| Sponsor | Montefiore Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Detemir: Role in Type 1 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Detemir and RAI injection CI brief — competitive landscape report
- Insulin Detemir and RAI injection updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI
Frequently asked questions about Insulin Detemir and RAI injection
What is Insulin Detemir and RAI injection?
Insulin Detemir and RAI injection is a Small molecule drug developed by Montefiore Medical Center.
Who makes Insulin Detemir and RAI injection?
Insulin Detemir and RAI injection is developed and marketed by Montefiore Medical Center (see full Montefiore Medical Center pipeline at /company/montefiore-medical-center).
What development phase is Insulin Detemir and RAI injection in?
Insulin Detemir and RAI injection is FDA-approved (marketed).